MTOR and prostate carcinoma: Potiron et al. reported that the dual PI3 K/mTOR inhibitor BEZ235 imparts a radio-sensitizing effect on prostate cancer cells under normoxia and hypoxia; the effect observed under hypoxia was also synergistic [26], which was in agreement with our results.